The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As the corporate earnings season progresses, markets are closely monitoring financial reports from the healthcare and consumer sectors to gauge resilience against operational headwinds. According to reports from Zacks Investment Research, analysts estimate that Medtronic (MDT) will report a decline in earnings in its upcoming financial report. Similarly, estimates suggest a likely decline in earnings for PVH Corp, as analysts note that both companies currently lack the specific combination of factors typically associated with an earnings beat.
Sign in to access this content
Sign InThis cautious outlook arrives as the medical device sector faces rising input costs, while the apparel industry grapples with fluctuating global demand; for instance, PVH peer Ralph Lauren recently reported slowing sales growth in key international markets per market data. Comparing current estimates to prior periods, inflationary pressures continue to weigh on profit margins, supporting analyst expectations for a year-over-year contraction in earnings per share for both entities.
In the markets, investors are watching key technical levels for MDT and PVH as they approach their respective reporting dates. According to the economic calendar, the release of the US Manufacturing PMI (May 21, 2026) will be a critical catalyst, potentially providing further insight into production costs and industrial demand that could influence sentiment for healthcare and retail stocks ahead of their earnings disclosures.
Update: Goldman Sachs has reinstated coverage on Medtronic (MDT) with a Neutral rating and a price target of $84, noting that the stock is currently trading at a 10% discount relative to its large-cap MedTech peers. Furthermore, analysts project organic revenue growth of 5% for the company, aligning with the sector average and providing a more stabilized outlook amid broader industry challenges.
Update: Options market data indicates an implied move of 4.1% for Medtronic (MDT) shares following its scheduled earnings release on June 3, 2026. This volatility projection is significant given that MDT has exceeded implied moves in 6 of its last 8 earnings reports, notably experiencing a 5.2% decline during its February 2026 reporting cycle.